Andere talen Lineage Cell Therapeutics, Inc.

Aandelen

LCTX

US53566P1093

Beurs gesloten - Nyse Andere beurzen 22:00:00 25-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,9141 ^USD	-0,90%		+2,71%	-16,14%

21/05	Lineage Cell Therapeutics, Inc. Kondigt updates aan voor het 2e Jaarlijkse Spinal Cord Injury Investor Symposium	CI
09/05	Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Lineage Cell Therapeutics : Changes in Registrant’s Certifying Accountant	17/06
Lineage Cell Therapeutics : Amendments to Articles of Incorporation or Bylaws; Submission of Matters to a Vote of Security Holder	17/06
Lineage to Present at 2024 BIO International Convention	30/05
Lineage Cell Therapeutics : FORM 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP CULLEY BRAIN M	29/05
Lineage Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	21/05
Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium	21/05
Lineage Cell Therapeutics : Opinion of Sheppard Mullin Richter & Hampton, LLP relating to the legality of the ATM Shares	21/05
Lineage Cell Therapeutics : Prospectus disclosing information, facts, events	21/05
Lineage Cell Therapeutics : Immediate Report	11/05
Lineage Cell: Q1 Earnings Snapshot	09/05
Earnings Flash (LCTX) LINEAGE CELL THERAPEUTICS Reports Q1 Revenue $1.4M, vs. Street Est of $1.36M	09/05
Lineage Cell Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Lineage Cell Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update	09/05
LINEAGE CELL - OPREGEN PHASE 1/2A CLINICAL STUDY 24-MONTH VISUAL ACUITY RESULTS FEATURED AT 2024 RETINAL CELL AND GENE THERAPY INNOVATION SUMMIT	07/05
OpRegen® (RG6501) Phase 1/2a Clinical Study 24-Month Visual Acuity Results Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit	06/05
Lineage Cell Therapeutics, Inc. Announces 24 Month Visual Acuity Results Featured At 2024 Retinal Cell & Gene Therapy Innovation Summit	06/05
Lineage Cell Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024	02/05
LINEAGE RECEIVES GRANT FROM CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE	01/05
Lineage Cell Therapeutics : Immediate Report	30/04
Lineage Cell Therapeutics : Additional proxy soliciting materials - definitive	30/04

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Lineage Cell Therapeutics, Inc.

Aandelen

LCTX

US53566P1093

Andere talen

Filters